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Amyotrophic lateral sclerosis is a neurodegenerative disorder characterized by progressive loss of upper and lower motor
neurons, with a median survival of 2–3 years. Although various phenotypic and research diagnostic classiﬁcation systems
exist and several prognostic models have been generated, there is no staging system. Staging criteria for amyotrophic lateral
sclerosis would help to provide a universal and objective measure of disease progression with beneﬁts for patient care, resource
allocation, research classiﬁcations and clinical trial design. We therefore sought to deﬁne easily identiﬁed clinical milestones
that could be shown to occur at speciﬁc points in the disease course, reﬂect disease progression and impact prognosis and
treatment. A tertiary referral centre clinical database was analysed, consisting of 1471 patients with amyotrophic lateral sclerosis
seen between 1993 and 2007. Milestones were deﬁned as symptom onset (functional involvement by weakness, wasting,
spasticity, dysarthria or dysphagia of one central nervous system region deﬁned as bulbar, upper limb, lower limb or diaphrag-
matic), diagnosis, functional involvement of a second region, functional involvement of a third region, needing gastrostomy and
non-invasive ventilation. Milestone timings were standardized as proportions of time elapsed through the disease course using
information from patients who had died by dividing time to a milestone by disease duration. Milestones occurred at predictable
proportions of the disease course. Diagnosis occurred at 35% through the disease course, involvement of a second region at
38%, a third region at 61%, need for gastrostomy at 77% and need for non-invasive ventilation at 80%. We therefore propose
a simple staging system for amyotrophic lateral sclerosis. Stage 1: symptom onset (involvement of ﬁrst region); Stage 2A:
diagnosis; Stage 2B: involvement of second region; Stage 3: involvement of third region; Stage 4A: need for gastrostomy; and
Stage 4B: need for non-invasive ventilation. Validation of this staging system will require further studies in other populations, in
population registers and in other clinic databases. The standardized times to milestones may well vary between different studies
and populations, although the stages themselves and their meanings are likely to remain unchanged.
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Introduction
Amyotrophic lateral sclerosis (ALS) is a neurodegenerative disorder
characterized by progressive loss of upper and lower motor neu-
rons, with a median survival of 2–3 years (Kiernan et al., 2011).
Although various phenotypic and research diagnostic classiﬁcation
systems exist and several prognostic models have been generated,
there is no staging system. For example, the El Escorial criteria
(Brooks, 1994) and their subsequent derivatives use the relative
burden of upper and lower motor neuron signs for classiﬁcation of
the clinical certainty of the diagnosis of ALS, but it is possible to
have advanced disease and a less certain El Escorial category, and
the criteria cannot therefore be used for staging.
Staging criteria are usually simple and deﬁne clinical milestones
in the course of a disease that reﬂect severity, prognosis and op-
tions for treatment. Although the ALS Functional Rating Scale
measures severity of disability as deﬁned by function and progno-
sis, the monitored events cannot be regarded as simple staging
milestones because many different modalities are assessed and it is
really a disability scale producing a single aggregate score that
correlates with functional progression (Group TAPI-IS, 1996;
Cedarbaum et al., 1999).
Similarly, there have been many models of ALS that use clinical
factors at presentation for phenotypic classiﬁcation and prediction
of survival, but these are not staging criteria as there are no mile-
stones (Boman and Meurman, 1967; Mulder and Howard, 1976;
Mortara et al., 1984; Ganesalingam et al., 2009; Turner et al.,
2009).
Staging criteria for ALS would help to provide a universal and
objective measure of disease progression with beneﬁts for patient
care, resource allocation, research classiﬁcations and clinical trial
design. We therefore sought to identify clinical milestones that
could be shown to occur at speciﬁc points in the disease course,
reﬂect disease progression and impact prognosis and treatment.
Such milestones could then form the basis of a staging system
for ALS.
Materials and methods
Patient selection
The study had ethical approval from the institutional Research Ethics
Committee (SLAM/IOP 222/02) and patients were included after in-
formed written consent. A tertiary referral centre clinical database con-
sisting of patients with ALS seen between 1993 and 2007 was
analysed. The diagnosis was made by the referring neurologist or at
the tertiary centre after full investigation to exclude other conditions.
All patients met the revised El Escorial-Arlie House Criteria (Brooks
et al., 2000) for ALS, and also included those with pure lower and
upper motor neuron syndromes. For patients seen before 2002, the El
Escorial category was reclassiﬁed retrospectively. Patients with clinically
obvious dementia at onset were excluded.
Methods and deﬁnitions
Patients were classiﬁed as having limb, bulbar or diaphragmatic onset
ALS. For the purposes of analysis, those with diaphragmatic onset
were classiﬁed with those with limb onset because of the common
spinal basis of lower motor neuron degeneration. ALS milestones for
investigation as potential staging criteria were selected on the basis of
being easily clinically available by being routinely collected at any clin-
ical visit, straightforward to deﬁne in terms of presence or absence of
involvement, and useful for phenotypic classiﬁcation (Wijesekera et al.,
2009). Milestones were deﬁned as symptom onset (functional involve-
ment by weakness, wasting, spasticity, dysarthria or dysphagia of one
CNS region deﬁned as bulbar, upper limb, lower limb or diaphragmat-
ic), diagnosis, functional involvement of a second region, functional
involvement of a third region, needing gastrostomy and non-invasive
ventilation. As wasting was almost always associated with weakness,
and for patients with ALS spasticity manifests as weakness, we did not
differentiate between those patients whose onset was not weakness,
but rather spasticity or wasting without weakness. Timing of involve-
ment was based on the date of onset of symptoms and dates of
development of functionally signiﬁcant symptoms in a second and
third region, which were gathered from the clinical history. Diagnosis
was deﬁned as a conﬁrmed diagnosis of ALS made either by the
referring neurologist or at the tertiary centre, as recorded in the case
records. The need for gastrostomy was deﬁned as the time gastros-
tomy or nasogastric feeding was provided or refused. The need for
non-invasive ventilation was deﬁned as the time non-invasive ventila-
tion was provided, trialled or refused.
Milestone timings were standardized as proportions of time elapsed
through the disease course using information from patients who had
died by dividing time to a milestone by disease duration, a similar
method to that used in a previous study of timings of medical inter-
ventions (Bromberg et al., 2010). Thus the time to each milestone was
a value between 0 and 1, with 0 being symptom onset and 1 being
death. Date of death was ascertained by clinic records, death certiﬁ-
cates and contact with the patient’s registered general practitioner.
The highest milestone recorded at last follow-up was used. Riluzole
use was also recorded and deﬁned as any use longer than 2 weeks.
Statistical analysis
Variables were expressed as mean [95% conﬁdence interval (CI)].
Standardized times were compared by Student’s t-test for two
groups and one-way analysis of variance (ANOVA) for three or
more groups, with subsequent post-hoc Dunnett tests. Variables that
were non-normally distributed were normalized by log transformation.
Non-parametric tests were used if transformation did not result in
normality. Survival analysis was by Kaplan–Meier product limit distri-
bution, with survival measured from clinical milestone to death or
censor date. Analyses were performed in SPSS v17.0 (SPSS Inc).
Model validation
Construct validity (Smith, 2005) was tested by using the system to
examine survival in the entire cohort, looking at median survival and
5-year survival in those with limb onset and bulbar onset ALS.
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Patient characteristics
There were 1471 patients with ALS. Twelve were excluded on the
basis of cognitive impairment. Of the remaining 1459, 371
(25.4%) had bulbar onset ALS, 1088 (74.6%) had limb onset
ALS and none had diaphragmatic onset. There were 892 males
(61.2%) and 577 females (38.8%), with a male-to-female ratio of
1.9 in those with limb onset and 0.9 in those with bulbar onset.
Mean age at onset was 57.4 years (95% CI 56.8–58.07). By
Kaplan–Meier analysis, the median survival was 42.3 months
(95% CI 39.8–45.0, range 4–274) for the entire population. The
median survival was 48.3 months (95% CI 45.0–51.7, range
4–274) for those with limb onset and 30.8 months (95% CI
28.5–33.0, range 6–261) for those with bulbar onset. One thou-
sand and sixty-seven patients had died at the end of follow-up,
295 with bulbar onset and 772 with limb onset. There was com-
plete information for 1061 patients. Of the remainder, 238 were
alive at the end of the study and could not therefore have mile-
stones calculated as a proportion of disease duration, and 160
patients had been lost to follow-up.
The characteristics of the patients who had died were different
from those not included in subsequent analysis because they were
either still alive or had been lost to follow-up. Median age of onset
was 60 years for those who had died, 54 years for those alive and
56 years for those lost to follow-up. Median diagnostic delay was
11 months for those who had died, 16 months for those alive and
15 months for those lost to follow-up.
Times to each milestone
Mean duration and standardized time from onset to every clinical
milestone is given in Table 1 and displayed graphically in Fig. 1.
Most patients had passed 41 milestone; we could therefore either
analyse the timing of the last milestone reached or the timing of
every milestone reached. Here, we report only the results of using
the last milestone recorded for each patient, but using every avail-
able milestone from each patient does not substantially alter any
of the results (Table 1).
Although milestones were reached at relatively predictable times,
some tended to occur at similar time points to each other (Fig. 1,
Tables 1 and 2). For example, the time to diagnosis was not par-
ticularly different from the time that a second region became weak.
Interestingly, the need for gastrostomy did not seem to occur at a
different time from the need for respiratory support, but because
the ease of diagnosis and the timing of subsequent spread could be
different for those with bulbar and limb onset, we examined
whether milestones were reached at different times in these
groups (Table 2). We found gastrostomy was needed before
non-invasive ventilation for patients with bulbar onset, but after
Table 1 Time taken to reach each milestone in patients who had died
n Mean milestone timing (months) Standardized mean Standardized
median
Last recorded milestone
Diagnosis 87 13.5 (11.3–15.7) 0.37 (0.33–0.42) 0.35 (0.24–0.47)
Involvement of second region 283 17.7 (15.5–19.8) 0.40 (0.37–0.42) 0.38 (0.20–0.58)
Involvement of third region 356 23.3 (20.8–25.7) 0.59 (0.57–0.62) 0.61 (0.39–0.82)
Need for gastrostomy 207 27.7 (25.1–30.2) 0.76 (0.73–0.78) 0.77 (0.65–0.90)
Need for non-invasive ventilation 134 30.3 (26.4–34.2) 0.75 (0.72–0.79) 0.80 (0.63–0.92)
Every milestone
Diagnosis 1061 15.2 (14.3–16.1) 0.41 (0.39–0.42) 0.38 (0.24–0.55)
Involvement of second region 958 14.7 (13.6–15.8) 0.35 (0.34–0.37) 0.32 (0.14–0.53)
Involvement of third region 609 22.8 (21.1–24.5) 0.58 (0.56–0.60) 0.60 (0.37–0.80)
Need for gastrostomy 232 27.3 (25.0–29.7) 0.76 (0.73–0.78) 0.77 (0.65–0.90)
Need for non-invasive ventilation 163 31.5 (27.8–35.1) 0.76 (0.73–0.79) 0.80 (0.65–0.92)
Means are given with 95% CI of the mean in brackets. The standardized median is given with the interquartile range of the sample in brackets.
Figure 1 Boxplot showing standardized times to last recorded
milestone (where 0 is onset of disease and 1 is death) for each
stage in the entire cohort with ALS. Stage 1 (onset) is not
explicitly shown but occurs at the origin; 2A = diagnosis;
2B = second region involved; 3 = third region involved;
4A = gastrostomy needed; 4B = respiratory support
(non-invasive ventilation) needed. The line marks the median
with the shaded box showing the interquartile range.
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Furthermore, in patients, diagnosis tended to occur at the same
time as a second region became weak, but involvement of a third
region occurred earlier for patients with bulbar onset (0.45 for
bulbar onset and 0.63 for limb onset, respectively; P = 1.1  10
7).
The use of riluzole also inﬂuenced timings. In limb onset ALS, the
standardized time to diagnosis in patients on riluzole (0.29) was
signiﬁcantly earlier than in patients not on riluzole (0.39;
P = 0.035 by Mann–Whitney test). This was not observed for
those with bulbar onset ALS, but the sample size was smaller and
therefore had less power. There was no effect on other milestones.
Validity of the system for staging
There is considerable evidence that the system is validated for sta-
ging. Construct validity is the extent to which a system measures
what it is supposed to measure (Smith, 2005). For the milestones to
be useful for staging, they should correspond correctly to survival
times from the milestone to death or censor date in the entire cohort,
not just those who have died. We therefore performed Kaplan–
Meier survival analysis (Table 3 and Fig. 2). In the ALS cohort overall,
the result clearly shows the groups can be distinguished and this is
also apparent for the limb onset ALS and bulbar onset subgroups,
consistent with the system having construct validity.
Furthermore, we examined 5-year survival from each milestone.
If the system has construct validity, earlier stages should show bias
towards individuals with a propensity for longer survival, and later
stages should be biased towards those with shorter survival, which
is what we observed (Table 3).
Finally, the fact that using every available milestone or just the
last recorded milestone makes very little difference to the results is
evidence of concurrent validity (Table 1).
Discussion
We have shown that simple clinical milestones tend to occur at
predictable times within the natural disease progression of ALS.
Weakness in a second region, weakness in a third region and
the need for gastrostomy or respiratory support occur at distinct
times, corresponding to 40, 60 and 80% of the disease course,
respectively, with diagnosis tending to occur, in our centre, at
35% of the way through. Gastrostomy is on average needed
before respiratory support for patients with bulbar onset, but the
opposite is true for patients with limb onset. We therefore propose
the following simple staging system for ALS:
Stage 1: Symptom onset (involvement of ﬁrst region).
Stage 2A: Diagnosis.
Stage 2B: Involvement of a second region.
Stage 3: Involvement of a third region.
Stage 4A: Need for gastrostomy.
Stage 4B: Need for respiratory support (non-invasive ventilation).
The highest stage is taken if needed. For example, someone
presenting with profound respiratory failure requiring non-invasive
ventilation would have Stage 4B ALS, not Stage 2A.
Table 2 Standardized times to milestones in patients with bulbar and limb onset ALS
Last recorded milestone Bulbar onset ALS Limb onset ALS
n Milestone timing n Milestone
timing
Diagnosis 28 0.38 (0.41–0.46) 59 0.37 (0.32–0.42)
Involvement of second region 58 0.39 (0.32–0.45) 225 0.40 (0.37–0.43)
Involvement of third region 71 0.45 (0.40–0.51) 285 0.63 (0.60–0.66)
Need for gastrostomy 106 0.71 (0.68–0.74) 101 0.81 (0.77–0.84)
Need for non-invasive ventilation 32 0.81 (0.77–0.86) 102 0.73 (0.69–0.78)
95% CIs are shown in brackets. Time to involvement of the third region is signiﬁcantly different between those with bulbar and those with limb onset ALS. The need for
gastrostomy in bulbar onset patients occurs at the equivalent time to the need for respiratory support in limb onset patients, and vice versa.
Table 3 Kaplan–Meier analysis of survival from each milestone
Last recorded milestone Bulbar onset ALS Limb onset ALS
Median (months) 5 year (%) Median (months) 5 year (%)
Diagnosis 19 20.5 59 49.9
Involvement of second region 19 17.5 28 29.0
Involvement of third region 13 9.8 13 12.3
Need for gastrostomy 9 6.4 6 4.2
Need for non-invasive ventilation 3 5.9 8 6.0
The non-standardized median survival and 5-year survival is given from each milestone for bulbar onset and limb onset ALS in the entire cohort. The observed values provide
supportive evidence of construct validity.
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to diagnosis may well differ in other health systems or clinics,
whereas standardized time to second region is likely to be similar
across all centres. The naming of the Stage 4 milestones is poten-
tially problematic. Overall, there is no difference between the stan-
dardized time to gastrostomy and respiratory support (Table 1) but
this hides the fact that the order in which they occur differs between
those with bulbar and those with limb onset (Table 2). Numbering
them as Stages 4 and 5 would not therefore lead to a consistent
system, and in addition, it is very unusual for staging systems in
other diseases to have a Stage 5. We therefore propose using
Stage 4 for both but with a sufﬁx to allow separation and recogni-
tion that the events are separate milestones.
This staging system is easy to use because it corresponds both
to information relevant to the neurologist and symptoms reported
by the patient. It differs from the El Escorial classiﬁcation (Brooks,
1994; World Federation of Neurology, 1995) because there is no
requirement for upper and lower motor neuron involvement,
simply evidence of neurological weakness. For example, someone
with a brisk jaw jerk and dysarthria, wasting of the small hand
muscles, lower limb spasticity and brisk limb reﬂexes would have El
Escorial ‘possible ALS’ on the basis of only one functional region
showing both upper and lower motor neuron involvement, but
would have Stage 3 ALS on the basis of involvement of three
functional regions. Similarly, someone with an isolated but
severe respiratory onset at presentation is at Stage 4B, despite
having El Escorial ‘possible ALS’ at best. It is well recognized
that a patient might require non-invasive ventilation or even die
with a ‘possible ALS’ diagnosis (Ince et al., 1998), whereas it
would be impossible for this situation to arise without the patient
having reached Stage 4B.
Progression through the disease stages at predictable times is
consistent with previous observations that disease progression
is curvilinear (Gordon et al., 2010), and that prognosis is pre-
dictable from the rate of early symptom progression or diag-
nostic delay (Chio et al., 2002; Turner et al., 2002). While
we recognize that, for example, time to gastrostomy is not
the same as nutritional decline, it is a milestone reached after
other nutritional interventions such as changes to dietary consist-
ency and the use of fortiﬁed supplements have been tried and is
therefore likely to occur at about the same disease stage. A study
using a similar methodology of examining events as a function of
proportion of disease elapsed, found that medical equipment needs
also occur at predictable time points (Bromberg et al., 2010).
A weakness of this study is that we have used a prevalent cohort
rather than an incident cohort to develop the milestones. Prevalent
cohorts differ in many ways from incident cohorts. For example,
they tend to be younger, live longer, have a higher proportion of
male patients and fewer with bulbar onset (Huisman et al., 2011).
We have used standardized timings as a proportion between onset
and death to generate the staging system, but it is possible that such
timings differ between cohorts of different ages, sex proportions
and phenotypes. The order of the milestones is very unlikely to
differ, since one cannot have three regions affected before two re-
gions, and interventions such as non-invasive ventilation or gastros-
tomy tend to occur towards the end of life, but the study should be
repeated in an incident cohort to explore cohort effects, if any, on
the standardized timings.
A further weakness is that we have not included a measure of
cognitive impairment. Cognitive impairment in ALS does not occur
as a ﬁxed event that can act as a milestone as it can happen at any
point in the disease course, and may vary from no impairment to
frank dementia. Thus, although cognitive impairment is an import-
ant prognostic, diagnostic and functional factor, it cannot be easily
integrated into a staging system because it does not fulﬁl one of the
three requirements, that of occurring at a predictable time. The
staging system is ﬂexible enough to accommodate this in the
future if needed however, for example by the addition of a sufﬁx
such as ‘CI’ to the stage to denote cognitive impairment.
A validated ALS staging system has several beneﬁts. Each stage
requires different types of professional and institutional resources
(Radunovic et al., 2007; Zoccolella et al., 2007; Pinto et al.,
2009), with Stage 1 requiring access to health care diagnostic
services, Stages 2 and 3 increasing use of the multidisciplinary
team, and Stage 4 requiring intervention, end of life palliation
and care. Staging can therefore be used to easily assess resource
provision in relation to need.
Clinical stage can also be used as a secondary endpoint for
clinical trials. Using a functional secondary endpoint such as the
ALS Functional Rating Scale may result in bias because it can only
be measured in those remaining alive who by necessity have a
better score, and it will therefore tend to be the same in each
treatment group regardless of the effect of therapy. Statistical
methods exist to work around this problem (Henderson et al.,
2000), but using standardized time to a particular stage would
not suffer from this bias and might allow assessment of what
stage treatment exerts it maximal effect. For example, in this
study, time to Stage 2A in patients with limb onset was reached
Figure 2 Kaplan–Meier curve showing survival for entire cohort
from last recorded milestone to death or censor date. The
separation of the curves is evidence of construct validity.
Blue = diagnosis; green = second region involved; grey = third
region involved; black = gastrostomy needed; purple = respira-
tory support needed.
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with 0.39 for those not taking riluzole. There are three possible
interpretations of this. It might be a false positive (we have per-
formed four independent and four dependent tests and so there is a
multiple testing burden), but the alternatives are that those who
subsequently take riluzole are seen more quickly perhaps because
they are more motivated, or that the overall survival is increased
following diagnosis and treatment (Bensimon et al., 1994), so the
proportion of time at which diagnosis occurs comes earlier. We can
test this by looking at the actual time to diagnosis in each group. If
the standardized time is reduced in one group but the actual times
are equal, this suggests the denominator is larger (overall disease
length is longer) in those with the smaller standardized time to
diagnosis. We ﬁnd the actual time is also shorter suggesting that
we are not observing a survival effect of riluzole but a bias.
Validation of this staging system will require further studies in
other populations, in population registers and in other clinic data-
bases. The standardized times to milestones may vary between
different studies and populations, although the stages themselves
and their meanings are likely to remain unchanged.
In conclusion, we propose a partially validated staging system
for ALS based on simple clinical milestones of the natural history
of ALS where each stage reﬂects the severity of the disease. We
recommend validation in a larger population-based prospective
cohort. This system may be of use for clinical practice, resource
allocation and clinical trials.
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